Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 259


N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues.

Nichols DE, Sassano MF, Halberstadt AL, Klein LM, Brandt SD, Elliott SP, Fiedler WJ.

ACS Chem Neurosci. 2015 Jan 21. [Epub ahead of print]


The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo.

White KL, Robinson JE, Zhu H, DiBerto JF, Polepally PR, Zjawiony JK, Nichols DE, Malanga CJ, Roth BL.

J Pharmacol Exp Ther. 2015 Jan;352(1):98-109. doi: 10.1124/jpet.114.216820. Epub 2014 Oct 15.


The Heffter Research Institute: past and hopeful future.

Nichols DE.

J Psychoactive Drugs. 2014 Jan-Mar;46(1):20-6.


Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia.

Martin DA, Marona-Lewicka D, Nichols DE, Nichols CD.

Neuropharmacology. 2014 Aug;83:1-8. doi: 10.1016/j.neuropharm.2014.03.013. Epub 2014 Apr 3.


New victims of current drug laws.

Nutt DJ, King LA, Nichols DE.

Nat Rev Neurosci. 2013 Dec;14(12):877. doi: 10.1038/nrn3530-c2. Epub 2013 Oct 23. No abstract available.


Effects of Schedule I drug laws on neuroscience research and treatment innovation.

Nutt DJ, King LA, Nichols DE.

Nat Rev Neurosci. 2013 Aug;14(8):577-85. doi: 10.1038/nrn3530. Epub 2013 Jun 12.


Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands.

Juncosa JI Jr, Hansen M, Bonner LA, Cueva JP, Maglathlin R, McCorvy JD, Marona-Lewicka D, Lill MA, Nichols DE.

ACS Chem Neurosci. 2013 Jan 16;4(1):96-109. doi: 10.1021/cn3000668. Epub 2012 Jul 17.


trans-2-(2,5-Dimethoxy-4-iodophenyl)cyclopropylamine and trans-2-(2,5-dimethoxy-4-bromophenyl)cyclopropylamine as potent agonists for the 5-HT(2) receptor family.

Pigott A, Frescas S, McCorvy JD, Huang XP, Roth BL, Nichols DE.

Beilstein J Org Chem. 2012;8:1705-9. doi: 10.3762/bjoc.8.194. Epub 2012 Oct 8.


Identification of a 2-phenyl-substituted octahydrobenzo[f]quinoline as a dopamine D₃ receptor-selective full agonist ligand.

Clark AH, McCorvy JD, Conley JM, Williams WK, Bekkam M, Watts VJ, Nichols DE.

Bioorg Med Chem. 2012 Nov 1;20(21):6366-74. doi: 10.1016/j.bmc.2012.08.058. Epub 2012 Sep 8.


Ligand-specific roles for transmembrane 5 serine residues in the binding and efficacy of dopamine D(1) receptor catechol agonists.

Chemel BR, Bonner LA, Watts VJ, Nichols DE.

Mol Pharmacol. 2012 May;81(5):729-38. doi: 10.1124/mol.111.077339. Epub 2012 Feb 14.


Comparison of the D₁ dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease.

McCorvy JD, Watts VJ, Nichols DE.

Psychopharmacology (Berl). 2012 Jul;222(1):81-7. doi: 10.1007/s00213-011-2625-5. Epub 2012 Jan 6.


Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor.

Halberstadt AL, Nichols DE, Geyer MA.

Psychopharmacology (Berl). 2012 Jun;221(4):709-18. doi: 10.1007/s00213-011-2616-6. Epub 2012 Jan 6.


Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines.

Cueva JP, Chemel BR, Juncosa JI Jr, Lill MA, Watts VJ, Nichols DE.

Eur J Med Chem. 2012 Feb;48:97-107. doi: 10.1016/j.ejmech.2011.11.039. Epub 2011 Dec 3.


Assessment of dopamine D₁ receptor affinity and efficacy of three tetracyclic conformationally-restricted analogs of SKF38393.

Clark AH, McCorvy JD, Watts VJ, Nichols DE.

Bioorg Med Chem. 2011 Sep 15;19(18):5420-31. doi: 10.1016/j.bmc.2011.07.057. Epub 2011 Aug 3.


A 5-HT(2C) receptor antagonist potentiates a low dose amphetamine-induced conditioned place preference.

McCorvy JD, Harland AA, Maglathlin R, Nichols DE.

Neurosci Lett. 2011 Nov 7;505(1):10-3. doi: 10.1016/j.neulet.2011.07.036. Epub 2011 Jul 30.


Potential serotonin 5-HT(1A) and dopamine D(4) receptor modulation of the discriminative stimulus effects of amphetamine in rats.

Marona-Lewicka D, Nichols DE.

Behav Pharmacol. 2011 Sep;22(5-6):508-15. doi: 10.1097/FBP.0b013e328349fc31.


Probing the steric space at the floor of the D1 dopamine receptor orthosteric binding domain: 7α-, 7β-, 8α-, and 8β-methyl substituted dihydrexidine analogues.

Cueva JP, Gallardo-Godoy A, Juncosa JI, Vidi PA, Lill MA, Watts VJ, Nichols DE.

J Med Chem. 2011 Aug 11;54(15):5508-21. doi: 10.1021/jm200334c. Epub 2011 Jul 14.


Mapping the catechol binding site in dopamine D₁ receptors: synthesis and evaluation of two parallel series of bicyclic dopamine analogues.

Bonner LA, Laban U, Chemel BR, Juncosa JI, Lill MA, Watts VJ, Nichols DE.

ChemMedChem. 2011 Jun 6;6(6):1024-40. doi: 10.1002/cmdc.201100010. Epub 2011 Apr 28.


An animal model of schizophrenia based on chronic LSD administration: old idea, new results.

Marona-Lewicka D, Nichols CD, Nichols DE.

Neuropharmacology. 2011 Sep;61(3):503-12. doi: 10.1016/j.neuropharm.2011.02.006. Epub 2011 Feb 23.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk